{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:16:43Z","timestamp":1770895003150,"version":"3.50.1"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T00:00:00Z","timestamp":1548028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mayo Clinic Intramural","award":["T32DK007130"],"award-info":[{"award-number":["T32DK007130"]}]},{"name":"Mayo Clinic Intramural","award":["UL1TR000448"],"award-info":[{"award-number":["UL1TR000448"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>It is important to identify patients with inflammatory bowel disease [IBD] refractory to anti-tumour necrosis factor [TNF] therapy, to avoid potential adverse effects and to adopt different treatment strategies. We aimed to identify and validate clinical and genetic factors to predict anti-TNF response in patients with IBD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Mayo Clinic and Washington University IBD genetic association study cohorts were used as discovery and replicate datasets, respectively. Clinical factors included sex, age at diagnosis, disease duration and phenotype, disease location, bowel resection, tobacco use, family history of IBD, extraintestinal manifestations, and response to anti-TNF therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 474 patients with IBD treated with anti-TNF therapy, 41 [8.7%] were refractory to therapy and 433 [91.3%] had response. Multivariate analysis showed history of immunomodulator use (odds ratio 10.2, p = 8.73E-4) and bowel resection (odds ratio 3.24, p = 4.38E-4) were associated with refractory response to anti-TNF agents. Among genetic loci, two [rs116724455 in TNFSF4\/18, rs2228416 in PLIN2] were successfully replicated and another four [rs762787, rs9572250, rs144256942, rs523781] with suggestive evidence were found. An exploratory risk model predictability [area under the curve] increased from 0.72 [clinical predictors] to 0.89 after adding genetic predictors. Through identified clinical and genetic predictors, we constructed a preliminary anti-TNF refractory score to differentiate anti-TNF non-responders (mean [standard deviation] score, 5.49 [0.99]) from responders (2.65 [0.39]; p = 4.33E-23).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Novel and validated genetic loci, including variants in TNFSF, were found associated with anti-TNF response in patients with IBD. Future validation of the exploratory risk model in a large prospective cohort is warranted.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjz017","type":"journal-article","created":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T04:10:56Z","timestamp":1548043856000},"page":"1036-1043","source":"Crossref","is-referenced-by-count":23,"title":["Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients With Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"13","author":[{"given":"Ming-Hsi","family":"Wang","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica J","family":"Friton","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura E","family":"Raffals","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A","family":"Leighton","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabana F","family":"Pasha","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F","family":"Picco","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly C","family":"Cushing","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA"},{"name":"Division of Gastroenterology, Washington University School of Medicine, St. Louis, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Monroe","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Washington University School of Medicine, St. Louis, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Billy D","family":"Nix","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Washington University School of Medicine, St. Louis, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney D","family":"Newberry","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Washington University School of Medicine, St. Louis, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A","family":"Faubion","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,1,21]]},"reference":[{"key":"2020071700231138000_CIT0001","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"2020071700231138000_CIT0002","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1053\/j.gastro.2013.04.007","article-title":"Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn\u2019s and Colitis Epidemiology study","volume":"145","author":"Ng","year":"2013","journal-title":"Gastroenterology"},{"key":"2020071700231138000_CIT0003","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"2020071700231138000_CIT0004","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2020071700231138000_CIT0005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ajg.2010.392","article-title":"The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn\u2019s and Colitis Organisation: when to start, when to stop, which drug to choose, and how to predict response?","volume":"106","author":"D\u2019Haens","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2020071700231138000_CIT0006","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2020071700231138000_CIT0007","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn\u2019s disease: a systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2020071700231138000_CIT0008","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cgh.2011.02.008","article-title":"Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn\u2019s disease","volume":"9","author":"J\u00fcrgens","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020071700231138000_CIT0009","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/1756283X16638833","article-title":"Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease","volume":"9","author":"Kopylov","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"2020071700231138000_CIT0010","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1097\/MIB.0000000000001231","article-title":"Therapeutic drug monitoring during induction of anti-tumor necrosis factor therapy in inflammatory bowel disease: defining a therapeutic drug window","volume":"23","author":"Papamichael","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2020071700231138000_CIT0011","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"2020071700231138000_CIT0012","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/pgs.09.150","article-title":"Pathology practice and pharmacogenomics","volume":"11","author":"Trent","year":"2010","journal-title":"Pharmacogenomics"},{"key":"2020071700231138000_CIT0013","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"2020071700231138000_CIT0014","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/ng.3760","article-title":"Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease","volume":"49","author":"de Lange","year":"2017","journal-title":"Nat Genet"},{"key":"2020071700231138000_CIT0015","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/ajg.2011.19","article-title":"The prognostic power of the NOD2 genotype for complicated Crohn\u2019s disease: a meta-analysis","volume":"106","author":"Adler","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2020071700231138000_CIT0016","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10620-011-1977-3","article-title":"NOD2 polymorphism predicts response to treatment in Crohn\u2019s disease\u2013first steps to a personalized therapy","volume":"57","author":"Niess","year":"2012","journal-title":"Dig Dis Sci"},{"key":"2020071700231138000_CIT0017","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/gast.2002.34172","article-title":"NOD2\/CARD15 does not influence response to infliximab in Crohn\u2019s disease","volume":"123","author":"Vermeire","year":"2002","journal-title":"Gastroenterology"},{"key":"2020071700231138000_CIT0018","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2036.2004.01946.x","article-title":"Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab","volume":"20","author":"Pierik","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"2020071700231138000_CIT0019","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/gutjnl-2012-303557","article-title":"Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn\u2019s disease","volume":"63","author":"Guti\u00e9rrez","year":"2014","journal-title":"Gut"},{"key":"2020071700231138000_CIT0020","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ibd.20024","article-title":"Predictive model for the outcome of infliximab therapy in Crohn\u2019s disease based on apoptotic pharmacogenetic index and clinical predictors","volume":"13","author":"Hlavaty","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"2020071700231138000_CIT0021","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2036.2005.02635.x","article-title":"Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn\u2019s disease","volume":"22","author":"Hlavaty","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"2020071700231138000_CIT0022","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/ajg.2010.95","article-title":"Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis","volume":"105","author":"J\u00fcrgens","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2020071700231138000_CIT0023","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1053\/gast.2001.23966","article-title":"ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn\u2019s disease","volume":"120","author":"Taylor","year":"2001","journal-title":"Gastroenterology"},{"key":"2020071700231138000_CIT0024","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2217\/pgs.15.90","article-title":"Association between TNF-\u03b1 [-308 A\/G, -238 A\/G, -857 C\/T] polymorphisms and responsiveness to TNF-\u03b1 blockers in spondyloarthropathy, psoriasis and Crohn\u2019s disease: a meta-analysis","volume":"16","author":"Song","year":"2015","journal-title":"Pharmacogenomics"},{"key":"2020071700231138000_CIT0025","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/gas.37.7.818.824","article-title":"A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism","volume":"37","author":"Louis","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"2020071700231138000_CIT0026","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/sj.tpj.6500091","article-title":"Pharmacogenetic investigation of the TNF\/TNF-receptor system in patients with chronic active Crohn\u2019s disease treated with infliximab","volume":"2","author":"Mascheretti","year":"2002","journal-title":"Pharmacogenomics J"},{"key":"2020071700231138000_CIT0027","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"2020071700231138000_CIT0028","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"2020071700231138000_CIT0029","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/rheumatology\/ken034","article-title":"Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register","volume":"47","author":"Karlsson","year":"2008","journal-title":"Rheumatology [Oxford]"},{"key":"2020071700231138000_CIT0030","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/00365521.2014.928901","article-title":"Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?","volume":"50","author":"Gisbert","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"2020071700231138000_CIT0031","first-page":"131","article-title":"[Side effects and contraindications for biological therapy in inflammatory bowel disease]","volume":"67","author":"Troskot","year":"2013","journal-title":"Acta Med Croatica"},{"key":"2020071700231138000_CIT0032","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ibd.20144","article-title":"Assessment of reliability and validity of IBD phenotyping within the National Institutes of Diabetes and Digestive and Kidney Diseases [NIDDK] IBD Genetics Consortium [IBDGC]","volume":"13","author":"Dassopoulos","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"2020071700231138000_CIT0033","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/ar3204","article-title":"Promise and pitfalls of the Immunochip","volume":"13","author":"Cortes","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2020071700231138000_CIT0034","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/jhg.2015.94","article-title":"Genetics of autoimmune diseases: insights from population genetics","volume":"60","author":"Ramos","year":"2015","journal-title":"J Hum Genet"},{"key":"2020071700231138000_CIT0035","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3389\/fimmu.2015.00364","article-title":"Role of tumor necrosis factor superfamily in neuroinflammation and autoimmunity","volume":"6","author":"Sonar","year":"2015","journal-title":"Front Immunol"},{"key":"2020071700231138000_CIT0036","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4049\/jimmunol.162.1.486","article-title":"Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein","volume":"162","author":"Higgins","year":"1999","journal-title":"J Immunol"},{"key":"2020071700231138000_CIT0037","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/gut.2006.091181","article-title":"GITR modulates innate and adaptive mucosal immunity during the development of experimental colitis in mice","volume":"56","author":"Santucci","year":"2007","journal-title":"Gut"},{"key":"2020071700231138000_CIT0038","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1194\/jlr.M500459-JLR200","article-title":"PPARalpha activators and fasting induce the expression of adipose differentiation-related protein in liver","volume":"47","author":"Dalen","year":"2006","journal-title":"J Lipid Res"},{"key":"2020071700231138000_CIT0039","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3748\/wjg.14.114","article-title":"A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis","volume":"14","author":"Liang","year":"2008","journal-title":"World J Gastroenterol"},{"key":"2020071700231138000_CIT0040","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1038\/ajg.2009.749","article-title":"Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity","volume":"105","author":"Pedersen","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2020071700231138000_CIT0041","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/ng.3359","article-title":"Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations","volume":"47","author":"Liu","year":"2015","journal-title":"Nat Genet"},{"key":"2020071700231138000_CIT0042","first-page":"433","article-title":"Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo","volume":"74","author":"Machnicki","year":"1993","journal-title":"Int J Exp Pathol"},{"key":"2020071700231138000_CIT0043","first-page":"469","article-title":"Sphingosine-1-phosphate in inflammatory bowel disease and colitis-associated colon cancer: the fat\u2019s in the fire","volume":"4","author":"Suh","year":"2015","journal-title":"Transl Cancer Res"},{"key":"2020071700231138000_CIT0044","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N Engl J Med"},{"key":"2020071700231138000_CIT0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/756290","article-title":"Peripheral blood based discrimination of ulcerative colitis and Crohn\u2019s disease from non-IBD colitis by genome-wide gene expression profiling","volume":"30","author":"Sipos","year":"2011","journal-title":"Dis Markers"},{"key":"2020071700231138000_CIT0046","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1002\/jcp.25709","article-title":"Up-regulation of transient receptor potential melastatin 6 channel expression by tumor necrosis factor-\u03b1 in the presence of epidermal growth factor receptor tyrosine kinase inhibitor","volume":"232","author":"Furukawa","year":"2017","journal-title":"J Cell Physiol"},{"key":"2020071700231138000_CIT0047","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"2020071700231138000_CIT0048","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/13\/8\/1036\/33131983\/jjz017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/13\/8\/1036\/33131983\/jjz017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T01:55:57Z","timestamp":1694570157000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/13\/8\/1036\/5299128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,21]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,1,21]]},"published-print":{"date-parts":[[2019,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz017","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,1,21]]}}}